Patents by Inventor Lee A. Flippin

Lee A. Flippin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Enhanced erythropoiesis and iron metabolism
    Patent number: 11680047
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erythropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: June 20, 2023
    Assignee: FibroGen, Inc.
    Inventors: Stephen J. Klaus, Al Y. Lin, Thomas B. Neff, Volkmar Guenzler-Pukall, Qingjian Wang, Lee A. Flippin, Michael P. Arend
  • Nitrogen-containing heteroaryl compounds and methods of use thereof
    Patent number: 11229637
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: January 25, 2022
    Assignee: FibroGen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE
    Publication number: 20210369702
    Abstract: The present invention provides methods for treating anemia in a subject having kidney failure by administering a compound that inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase.
    Type: Application
    Filed: August 5, 2021
    Publication date: December 2, 2021
    Applicant: FibroGen, Inc.
    Inventors: Stephen J. KLAUS, Al Y. LIN, Thomas B. NEFF, Qingjian WANG, Volkmar GUENZLER-PUKALL, Lee A. FLIPPIN, Michael P. AREND, Alex MELEKHOV
  • ENHANCED ERYTHROPOIESIS AND IRON METABOLISM
    Publication number: 20210107878
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erythropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Application
    Filed: December 23, 2020
    Publication date: April 15, 2021
    Inventors: Stephen J. Klaus, Al Y. Lin, Thomas B. Neff, Volkmar Guenzler-Pukall, Qingjian Wang, Lee A. Flippin, Michael P. Arend
  • NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20210060000
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-assocaited conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Application
    Filed: March 13, 2020
    Publication date: March 4, 2021
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • Enhanced erythropoiesis and iron metabolism
    Patent number: 10927081
    Abstract: The present invention relates to methods and compounds for regulating or enhancing erthropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
    Type: Grant
    Filed: January 30, 2018
    Date of Patent: February 23, 2021
    Assignee: FIBROGEN, INC.
    Inventors: Stephen J Klaus, Al Y. Lin, Thomas B. Neff, Volkmar Guenzler-Pukall, Qingjian Wang, Lee A. Flippin, Michael P. Arend
  • Nitrogen-containing heteroaryl compounds and methods of use thereof
    Patent number: 10646482
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: May 12, 2020
    Assignee: FibroGen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20190240213
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Application
    Filed: August 22, 2018
    Publication date: August 8, 2019
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • Nitrogen-containing heteroaryl compounds and methods of use thereof
    Patent number: 10092558
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: October 9, 2018
    Assignee: FibroGen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • METHODS FOR TREATING A NEUROLOGICAL DISORDER IN A SUBJECT USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) PROYL HYDROXYLASE
    Publication number: 20170312268
    Abstract: The present invention provides methods for treating anemia in a subject having kidney failure by administering a compound that inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase.
    Type: Application
    Filed: February 3, 2017
    Publication date: November 2, 2017
    Applicant: FibroGen, Inc.
    Inventors: Stephen J. KLAUS, Al Y. Lin, Thamas B. Neff, Qingjian Wang, Volkmar Guenzler-Pukall, Lee A. Flippin, Michael P. Arend, Alex Melekhov
  • METHODS OF TREATING CHRONIC RHINOSINUSITIS
    Publication number: 20170266228
    Abstract: The present invention provides methods of treating chronic rhinosinusitis that comprise administering a formulation of boric acid to the nasal and paranasal cavities of a patient in need. The present invention also provides for the use of a formulation comprising boric acid for the treatment of chronic rhinosinusitis.
    Type: Application
    Filed: June 7, 2017
    Publication date: September 21, 2017
    Inventor: Lee A. Flippin
  • Methods of treating chronic rhinosinusitis
    Patent number: 9744192
    Abstract: The present invention provides methods of treating chronic rhinosinusitis that comprise administering a formulation of boric acid to the nasal and paranasal cavities of a patient in need. The present invention also provides for the use of a formulation comprising boric acid for the treatment of chronic rhinosinusitis.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: August 29, 2017
    Inventor: Lee A. Flippin
  • Naphthyridine derivatives as inhibitors of Hypoxia inducible factor (HIF) hydroxylase
    Patent number: 9695170
    Abstract: The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: July 4, 2017
    Assignee: FibroGen, Inc.
    Inventors: Danny Ng, Michael P. Arend, Lee A. Flippin
  • NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20170035747
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Application
    Filed: April 19, 2016
    Publication date: February 9, 2017
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • METHODS OF TREATING CHRONIC RHINOSINUSITIS
    Publication number: 20160271173
    Abstract: The present invention provides methods of treating chronic rhinosinusitis that comprise administering a formulation of boric acid to the nasal and paranasal cavities of a patient in need. The present invention also provides for the use of a formulation comprising boric acid for the treatment of chronic rhinosinusitis.
    Type: Application
    Filed: May 29, 2015
    Publication date: September 22, 2016
    Inventor: Lee A. Flippin
  • 4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors
    Patent number: 9409892
    Abstract: The present invention relates to novel compounds of formula (I), and compositions capable of inhibiting PHD1 enzyme activity selectively over other isoforms, for example, PHD2 and/or PHD3 enzymes. The invention also relates to compounds of formula (I) for use in disorders such as muscle degeneration, colitis, IBD, and certain ischemias.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: August 9, 2016
    Assignee: FibroGen, Inc.
    Inventors: Wen-Bin Ho, Hongda Zhao, Shaojiang Deng, Danny Ng, Lee R. Wright, Min Wu, Xiaoti Zhou, Michael P. Arend, Lee A. Flippin
  • Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
    Patent number: 9387200
    Abstract: The present invention relates to novel compounds according to Formula I or II, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF). Formula (I) or (II).
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: July 12, 2016
    Assignee: FibroGen, Inc.
    Inventors: Xiaoti Zhou, Michael P. Arend, Min Wu, Lee A. Flippin
  • NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE
    Publication number: 20160159796
    Abstract: The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Application
    Filed: February 12, 2016
    Publication date: June 9, 2016
    Inventors: Danny Ng, Michael P. Arend, Lee A. Flippin
  • Nitrogen-containing heteroaryl compounds and methods of use thereof
    Patent number: 9339527
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: May 17, 2016
    Assignee: FibroGen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase
    Patent number: 9271970
    Abstract: The present disclosure relates to novel compounds, methods, and compositions capable of inhibiting HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: March 1, 2016
    Assignee: FIBROGEN, INC.
    Inventors: Danny Ng, Michael P. Arend, Lee A. Flippin